Evidence map›Paper›PMID 24045400›Full record

ArticleJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism2014

Cerebral arterial bolus arrival time is prolonged in multiple sclerosis and associated with disability.

David Paling, Esben Thade Petersen, Daniel J Tozer, Daniel R Altmann, Claudia A M Wheeler-Kingshott, Raju Kapoor, David H Miller, Xavier Golay

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03896217 (A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis), which is not on this map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03896217 phase2completednot on this mapstarted 2019, after this paper: background citation

A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis: Impact on Vascular Perfusion and Oxidative Damage

TypeinterventionalSponsorUniversity College, LondonRan2019 to 2023Enrolled40ConditionsSecondary Progressive Multiple SclerosisArmsSimvastatin
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Characterizing the time course of cerebrovascular reactivity in multiple sclerosis.Journal of neuroimaging : official journal of the American Society of Neuroimaging · 2022
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

David PalingDepartment of Neuroinflammation, UCL Institute of Neurology, Queen Square MS Centre, London, UK.
Esben Thade PetersenDepartment of Radiology and Radiotherapy E01.132, University Medical Centre Utrecht, Utrecht, The Netherlands.
Daniel J TozerDepartment of Neuroinflammation, UCL Institute of Neurology, Queen Square MS Centre, London, UK.
Daniel R Altmann1] Department of Neuroinflammation, UCL Institute of Neurology, Queen Square MS Centre, London, UK [2] Medical Statistics Department, London School of Hygiene and Tropical Medicine, London, UK.
Claudia A M Wheeler-KingshottDepartment of Neuroinflammation, UCL Institute of Neurology, Queen Square MS Centre, London, UK.
Raju KapoorDepartment of Neuroinflammation, UCL Institute of Neurology, Queen Square MS Centre, London, UK.
David H MillerDepartment of Neuroinflammation, UCL Institute of Neurology, Queen Square MS Centre, London, UK.
Xavier GolayDepartment of Brain Repair and Rehabilitation, UCL Institute of Neurology, Queen Square MS Centre, London, UK.
National Hospital for Neurology and Neurosurgery · GBUniversity College London · GBUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alterations in the overall cerebral hemodynamics have been reported in multiple sclerosis (MS); however, their cause and significance is unknown. While potential venous causes have been examined, arterial causes have not. In this study, a multiple delay time arterial spin labeling magnetic resonance imaging sequence at 3T was used to quantify the arterial hemodynamic parameter bolus arrival time (BAT) and cerebral blood flow (CBF) in normal-appearing white matter (NAWM) and deep gray matter in 33 controls and 35 patients with relapsing-remitting MS. Bolus arrival time was prolonged in MS in NAWM (1.0±0.2 versus 0.9±0.2 seconds, P=0.031) and deep gray matter (0.90±0.18 versus 0.80±0.14 seconds, P=0.001) and CBF was increased in NAWM (14±4 versus 10±2 mL/100 g/min, P=0.001). Prolonged BAT in NAWM (P=0.042) and deep gray matter (P=0.01) were associated with higher expanded disability status score. This study demonstrates alteration in cerebral arterial hemodynamics in MS. One possible cause may be widespread inflammation. Bolus arrival time was longer in patients with greater disability independent of atrophy and T2 lesion load, suggesting alterations in cerebral arterial hemodynamics may be a marker of clinically relevant pathology.

Indexed as

Persons with DisabilitiesAdolescentAdultAgedBlood Flow VelocityCase-Control StudiesCerebral ArteriesCerebrovascular CirculationDisability EvaluationFemaleHumansLinear ModelsMagnetic Resonance ImagingMaleMiddle AgedMultiple SclerosisSpin Labels

Identifiers

PMID24045400
PMCPMC3887342
OpenAlexW2045039754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.